Board approved audited standalone and consolidated financial results for FY26 ended March 31, 2026.
Recommended final dividend of ₹0.35 per share, totaling ₹1.50 per share including interim dividend.
Recognized ₹174.11 crore impairment loss and classified ₹736.97 crore Etalin HEP assets as held for sale.
Revenue includes ₹670.98 crore from prior years due to tariff orders for NJHPS and RHPS.